B of A Securities Initiates Coverage On Aardvark Therapeutics with Buy Rating, Announces Price Target of $22

Aardvark Therapeutics, Inc. +1.92%

Aardvark Therapeutics, Inc.

AARD

10.63

+1.92%

B of A Securities analyst Tim Anderson initiates coverage on Aardvark Therapeutics (NASDAQ: AARD) with a Buy rating and announces Price Target of $22.
Every question you ask will be answered
Scan the QR code to contact us
whatsapp
Also you can contact us via